18.81USD-4.32%Mkt Cap: 1.68B USDP/E: —Last update: 2026-06-01
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.68B USD
Enterprise Value1.72B USD
Revenue (TTM)217.17M USD
Gross Profit165.38M USD
Net Income (TTM)-285.42M USD
Revenue/Share2.492 USD
Last Price18.81 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees298
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS87164F1057
Valuation
P/E (Trailing)—
P/E (Forward)-41.63
PEG—
EV/EBITDA-7.68
EV/Revenue7.92
P/S7.99
P/B26.51
EPS (TTM)-2.79
EPS (Forward)-0.47
52W Range
8.58560% of range25.59
52W High25.59 USD
52W Low8.585 USD
Profitability
Gross Margin95.96%
Oper. Margin-52.73%
EBITDA Margin-103.04%
Profit Margin-165.60%
ROE-441.62%
ROA-53.88%
Growth
Revenue Growth223.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-322.98M USD
CapEx (TTM)187.00K USD
FCF Margin-85.65%
FCF Yield-11.10%
Net Debt-15.88M USD
Net Debt/EBITDA0.07
Balance Sheet
Debt/Equity5.34
Current Ratio5.47
Quick Ratio4.90
Book Value/Sh0.7390 USD
Cash/Share4.077 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)39.25 USD
Target Range29.00 USD – 57.00 USD
# Analysts12
Ownership
Shares Out.88.61M
Float79.03M
Insiders1.72%
Institutions116.13%
Short Interest
Short Ratio11.9d
Short % Float24.93%
Short % Out.24.50%
Shares Short21.71M
Short (prev mo.)20.97M
Technical
SMA 5022.20 (-15.3%)
SMA 20019.29 (-2.5%)
Beta0.41
S&P 52W Chg27.70%
Avg Vol (30d)1.53M
Avg Vol (10d)1.28M
Technical Indicators
RSI (14)41.1
MACD-0.6386
MACD Signal-0.6787
MACD Hist.+0.0401
BB Upper21.42 USD
BB Middle20.14 USD
BB Lower18.85 USD
BB Width12.80%
ATR (14)0.8918 USD
Vol Ratio (20d)0.23x